On July 23, 2026, Aprea Therapeutics received notification from Nasdaq that it remains non-compliant with the $1.00 minimum bid price requirement. The company has been granted an additional 180-calendar day extension, until January 19, 2027, to regain compliance. To avoid delisting, the common stock's closing bid price must be at least $1.00 for 10 consecutive business days within this period. Aprea Therapeutics is a biopharmaceutical company that develops therapies for rare diseases.

At the 2026 annual meeting of stockholders, Aprea Therapeutics, Inc. stockholders approved an amendment to the certificate of incorporation to authorize the Board of Directors to effect a reverse stock split of common stock at a ratio between one-for-three and one-for-eight. Aprea Therapeutics, Inc. is a biotechnology company that develops therapeutic solutions for patients with respiratory diseases.